Durability of Dapagliflozin vs. Glipizide as Add-On Therapies in T2DM Inadequately Controlled on Metformin: 4-Year Data   The efficacy, tolerability and safety of dapagliflozin was studied compared to glipizide over a period of 4 years. Dapagliflozin is a novel medication that is a highly selective inhibitor of SLGLT2 and reduces …

Boehringer Ingelheim Pharmaceuticals, Inc., and Eli Lilly and Company are working together to pave a new pathway for type 2 diabetes patients with the sodium glucose co-transporter 2 (SGLT2) inhibitor, empagliflozin. The investigational agent is currently in Phase III clinical trials focusing on four pivotal trials that have concluded with …

Canagliflozin Added on to Dipeptidyl Peptidase-4 Inhibitors or Glucagon-Like Peptide-1 Agonists With or Without Other Antihyperglycemic Agents in Type 2 Diabetes Mellitus (T2DM)   Canagliflozin is an SGLT2 inhibitor which was intended for treatment in diabetic type 2 patients. This analysis was a post hoc design and data was utilized …

Recently, I was chatting electronically with Irl B. Hirsch, MD, Diabetes Treatment and Teaching Chair at the University of Washington School of Medicine. I asked him if he had been using Invokana with his patients, and he sent me back this message: “No, not yet, and not likely to anytime soon …

David Joffe, BSPharm, CDE, Editor-in-chief, Diabetes In Control Lauren Self, University of Florida College of Pharmacy, PharmD Candidate When the finest, most talented endocrinologists get together for a conference, you can bet that there will be a lot of great information on the latest in diabetes care. This year it …

An abundance of excitement has surrounded the FDA approval of the sodium glucose cotransporter 2 inhibitor (SGLT2 –I), Invokana. So why did we need to introduce a 14th class of medication for treating diabetes? That answer was simple for Richard Aguilar, MD, Medical Director, Diabetes Nation, and Diabetes Care Foundation, …

In this set of Homerun Slides, we give you a brief overview of the functioning of this new class of drugs, and get into the specifics of the first drug in its class approved by the FDA, canagliflozin (Invokana)…. Link to download (.ppt format): SGLT-2 Inhibitors: A New Modality for Treating …

Andre McMahon, PharmD Candidate, University of Florida College of Pharmacy Dave Joffe, Editor-in-chief, Diabetes In Control The metabolic syndrome is associated with many risk factors for type 2 diabetes mellitus and cardiovascular complications which include: central obesity, elevated fasting glucose, elevated triglycerides, decreased high-density lipoprotein (HDL) cholesterol, and hypertension. When a …

The human body is able to maintain tight control of blood glucose despite varying glucose consumption, production, and utilization. Two key players involved in maintaining glucose homeostasis are the liver and the hormone insulin which affect each other through various direct and indirect mechanisms…. Insulin Physiology and Metabolism by the …

David Joffe, BSPharm, CDE, Editor-in-chief, Diabetes In Control The Endocrine Society has published a new set of recommendations on the definition of endocrine-disrupting chemicals (EDC) and screening programs for such chemicals.